Showing Results for: “diabetes”

Funding Cuts Could Create Unintended Consequences for People with Diabetes The National Institutes of Health (NIH) recently announced that it is limiting funding for indirect costs for research grants. These funds, generally provided to universities, medical centers, and other scientific organizations, help offset overhead expenses related to conducting research. Previously, the amount of NIH funding assigned for indirect costs varied and is now being reduced to a flat ratio of 15%. Effective today, this reduction will be applied to all new NIH grants and will result in funding cuts to the $9

The American Diabetes Association® (ADA) applauds Georgia Governor Brian P. Kemp for signing a bill allowing a broader population of Georgia’s Medicaid beneficiaries to be eligible for a continuous glucose monitor (CGM), a big win for those diagnosed with diabetes who are insulin dependent. CGMs continually monitor blood glucose (blood sugar), giving real-time updates through a device that is attached to a person’s body. People with diabetes who use a CGM have fewer instances of hypoglycemia (low blood glucose) and can achieve a lower A1C, an important indicator of glucose management. The

Today, the American Diabetes Association ® (ADA) and the Patient Advocate Foundation (PAF) proudly announce the opening of the diabetes fund, expanding PAF’s Co-Pay Relief Program (CPR) to serve people living with diabetes. The launch of this fund, made possible by the support of the ADA, provides financial assistance to people living with diabetes who meet the eligibility requirements to pay for co-pays, deductibles and co-insurance for doctors visits, medications, and testing related to the treatment and management of diabetes, and for medical insurance premiums. “The ADA has a long history

Exploratory Analysis from the SURPASS-4 Trial Data for Kidney Function with Tirzepatide Compared to Insulin Glargine A pre-specified exploratory analysis from the SURPASS-4 trial showed tirzepatide, a novel once-weekly medication for the treatment of diabetes, improved kidney outcomes for adults with type 2 diabetes who have increased cardiovascular risk. SURPASS-4 was part of the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide. Findings were presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Chronic kidney disease (CKD)

Reality show style competition showcases novel diabetes business ideas with potential funders as part of ADA 83 rd Scientific Sessions Today, the American Diabetes Association® (ADA) announced the winners of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas. The winners, Minutia, Oregon Health &

“La Asociación Americana de la Diabetes (ADA) es la principal defensora de la asequibilidad de la insulina y trabaja para garantizar que todas las personas con diabetes tengan acceso a la atención que necesitan. La ADA ha liderado el proceso de aprobación de límites de gastos compartidos para la insulina en 22 estados y en el Distrito de Columbia, así como el primer límite federal de copago en Medicare. Nos alienta que los principales fabricantes hayan tomado medidas para que la insulina sea más asequible, pero la lucha no ha terminado. Seguiremos defendiendo los esfuerzos en el Congreso y en

The Regional Advocacy Council Advocate of the Year award from the American Diabetes Association ® (ADA) honors individuals who demonstrate exceptional commitment to advancing diabetes advocacy at the state and community levels. The ADA proudly announces Don Feltham as the recipient of this inaugural award, recognizing his consistent engagement, dedication, and passion as a Diabetes Advocate. Feltham was honored during the 2026 Call to Congress in Washington, DC, where Diabetes Advocates from across the country gathered to meet with lawmakers and champion policies that improve the lives of

Initial data indicate that children presented with higher acuity compared to the previous year New data show that the incidence and acuity of type 2 diabetes in children increased significantly during the peak of the COVID-19 pandemic, with more pediatric patients hospitalized from March to December 2020 compared to the same time period in 2019. Findings from the retrospective chart review were presented as a late-breaking poster session at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Stay-at-home orders due to the COVID-19 pandemic exacerbated risk

Medicaid and Supplemental Nutrition Assistance Program (SNAP) provide critical access to care, medications, diabetes technology, and groceries for people with diabetes Today, Charles “Chuck” Henderson, chief executive officer at the American Diabetes Association ® (ADA), issued the following statement in response to the Senate’s passage of its reconciliation bill that would make substantial changes and cuts to critical federal health care and nutrition assistance programs. “The ADA is deeply concerned by the Senate’s changes to H.R. 1. If enacted, the bill would implement devastating cuts to

Last week, at its first-ever Cost of Care Summit, the American Diabetes Association ® (ADA) shared the results of a new study on Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race. The study, featuring analysis by Health Management Associates, finds that although access to CGMs provides potentially life-changing benefits for diabetes management, poorer, older, and Black Americans have less access to these devices than others. “It is disappointing to see that, today, access to vital diabetes management technology like CGMs is uneven and